Extrapolation of in vitro enzyme induction data to humans in vivo

Chemico-Biological Interactions

Volumn 107, Issue 1-2, 1997, Pages 109-121

  Kedderis, Gregory L ^a  

^a CIIT CENTERS FOR HEALTH RESEARCH   (United States)

Author keywords

Cytochrome P450 2E1; Enzyme induction; Furan; Hazardous chemical air pollutants; Hepatic blood flow limitation; Hepatocytes; Physiologically based pharmacokinetics; Xenobiotic biotransformation

Indexed keywords

CYTOCHROME P450 ISOENZYME; FURAN DERIVATIVE; LIVER ENZYME; TOXIC SUBSTANCE; XENOBIOTIC AGENT;

CALCULATION; CHEMICAL REACTION KINETICS; CONFERENCE PAPER; DRUG TRANSFORMATION; ENZYME INDUCTION; HUMAN; LIVER; LIVER BLOOD FLOW; NONHUMAN; POLLUTANT; XENOBIOTIC METABOLISM;

ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2E1; ENZYME INDUCTION; HUMANS; KINETICS; LIVER; MODELS, BIOLOGICAL; XENOBIOTICS;

ANIMALIA;

EID: 0030670353     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(97)00076-8     Document Type: Conference Paper

References (56)

1. A.H. Conney, Pharmacological implications of microsomal enzyme induction, Pharmacol. Rev. 19 (1967) 317-366.
2. J. Hunter, L.F. Chasseaud, Clinical aspects of microsomal enzyme induction, in: J.W. Bridges, L.F. Chasseaud (Eds.), Progress in Drug Metabolism, vol. 1, Wiley, London, 1976, pp. 129-191.
3. A.H. Conney, Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons, Cancer Res. 42 (1982) 4875-4917.
4. A. Breckenridge, Enzyme induction in humans. Clinical aspects - an overview, Pharmacol. Ther. 33 (1987) 95-99.
5. G.L. Kedderis, The role of the mixed-function oxidase system in the toxication and detoxication of chemicals: Relationship to chemical interactions, in: R.S. Goldstein, W.R. Hewitt, J.B. Hook (Eds.), Toxic Interactions, Academic, San Diego, 1990, pp. 31-60.
6. T.D. Porter, M.J. Coon, Cytochrome P450: Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms, J. Biol. Chem. 266 (1991) 13469-13472.
7. J.-Å. Gustafsson, A. Mode, G. Norstedt, P. Skett, Sex steroid induced changes in hepatic enzymes, Annu. Rev. Physiol. 45 (1983) 51-60.
8. D.R. Koop, Oxidative and reductive metabolism by cytochrome P450 2E1, FASEB J. 6 (1992) 724-730.
9. F.P. Guengerich, D.-H. Kim, M. Iwasaki, Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects, Chem. Res. Toxicol. 4 (1991) 168-179.
10. F.P. Guengerich, T. Shimada, Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes, Chem. Res. Toxicol. 4 (1991) 391-407.
11. J.L. Raucy, J.C. Kraner, J.M. Lasker, Bioactivation of halogenated hydrocarbons by cytochrome P450 2E1, Crit. Rev. Toxicol. 23 (1993) 1-20.
12. A.P. Li, P. Maurel, M.J. Gomez-Lechon, L.C. Cheng, M. Jurima-Romet, Preclinical evaluation of drug-drug interaction potential: Present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction, Chem. Biol. Interact. 107 (1997) 5-16 (this issue).
13. P.O. Seglen, Preparation of isolated rat liver cells, Methods Cell. Biol. 13 (1976) 29-83.
14. I.M. Arias, H, Popper, D. Schachter, D.A. Shafritz, The Liver: Biology and Pathobiology, Raven Press, New York, 1982.
15. A.D. Arms, C.C. Travis, Reference physiological parameters in pharmacokinetic modeling, US EPA/600/6-88/004, Final Report, NTIS, PB88196019, 1988.
16. R.E. Billings, R.E. McMahon, J. Ashmore, S.R. Wagle, The metabolism of drugs in isolated rat hepatocytes: A comparison with in vivo drug metabolism and drug metabolism in subcellular liver fractions, Drug Metab. Dispos. 5 (1977) 518-526.
17. A.E. Sirica, H.C. Pitot, Drug metabolism and effects of carcinogens in cultured hepatic cells, Pharmacol. Rev. 31 (1980) 205-228.
18. J.H. Lin, Y. Sugiyama, S. Awazu, M. Hanano, Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data, J. Pharmacokinet. Biopharm. 10 (1982) 649-661.
19. H.G. Oldham, R.J. Chenery, P. Standring, S.J. Norman, A. Garton, A.D. Ayrton, Drug metabolism kinetic studies in a hepatocyte model, Food Chem. Toxicol. 24 (1986) 761-762.
20. M.K. Bayliss, J.A. Bell, W.N. Jenner, K. Wilson, Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes, Biochem. Soc. Trans. 18 (1990) 1198-1199.
21. K. Singh, S.L. Tripp, A.W. Dunton, F.L. Douglas, A. Rakhit, Determination of in vivo hepatic extraction ratio from in vitro metabolism by rat hepatocytes, Drug Metab. Dispos. 19 (1991) 990-996.
22. G.L. Kedderis, M.A. Carfagna, S.D. Held, R. Batra, J.E. Murphy, M.L. Gargas, Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro, Toxicol. Appl. Pharmacol. 123 (1993) 274-282.
23. G.L. Kedderis, S.D. Held, M.L. Gargas, Prediction of chemical pharmacokinetics in vivo using freshly isolated hepatocytes in vitro, ISSX Proceedings 4 (1993) 61.
24. J.B. Houston, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance, Biochem. Pharmacol. 47 (1994) 1469-1479.
25. M. Kukan, S. Bezek, W.F. Pool, T.F. Woolf, Metabolic disposition of tacrine in primary suspensions of rat hepatocytes and in single-pass perfused liver: In vitro/in vivo comparisons, Xenobiotica 24 (1994) 1107-1117.
26. G.L. Kedderis, S.D. Held, Prediction of furan pharmacokinetics from hepatocyte studies: Comparison of bioactivation and hepatic dosimetry in rats, mice, and humans, Toxicol. Appl. Pharmacol. 140 (1996) 124-130.
27. T. Lave, S. Dupin, M. Schmitt, M. Kapps, J. Meyer, B. Morgenroth, R.C. Chou, D. Jaeck, P. Coassolo, Interspecies scaling of tolcapone, a new inhibitor of catechol-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans, Xenobiotica 26 (1996) 839-851.
28. P.D. Worboys, B. Brennan, A. Bradbury, J.B. Houston, Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition, Xenobiotica 26 (1996) 897-907.
29. P.O. Seglen, P.B. Gordon, A. Poli, Amino acid inhibition of the autophagic/lysosomal pathway of protein degradation in isolated rat hepatocytes, Biochim. Biophys. Acta 630 (1980) 103-118.
30. M.L. Gargas, R.J. Burgess, D.E. Voisard, G.H. Cason, M.E. Andersen, Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues, Toxicol. Appl. Pharmacol. 98 (1989) 87-99.
31. G.W. Jepson, D.K. Hoover, R.K. Black, J.D. McCafferty, D.A. Mahle, J.M. Gearhart, A partition coefficient determination method for nonvolatile chemicals in biological tissues, Fund. Appl. Toxicol. 22 (1994) 519-524.
32. I. Sjöholm, B. Ekman, A. Kober, I. Ljungstedt-Påhlman, B. Seiving, T. Sjödin, Binding of drugs to human serum albumin: Xl. The specificity of three binding sites as studied with albumin immobilized in microparticles, Mol. Pharmacol. 16 (1979) 767-777.
33. S.K.O. Teo, G.L. Kedderis, M.L. Gargas, Determination of tissue partition coefficients for volatile tissue-reactive chemicals: Acrylonitrile and its metabolise 2-cyanoethylene oxide, Toxicol. Appl. Pharmacol. 128 (1994) 92-96.
34. P.F. Hollenberg, Mechanisms of cytochrome P450 and peroxidase-catalyzed xenobiotic metabolism, FASEB J. 6 (1992) 686-694.
35. D.B. Northrop, Fitting enzyme-kinetic data to V/K, Anal. Biochem. 132 (1983) 457-461.
36. M.E. Andersen, Physiological modelling of organic compounds, Ann. Occup. Hyg. 35 (1991) 309-321.
37. M.L. Gargas, M.A. Medinsky, M.E. Andersen, Advances in physiological modeling approaches for understanding the disposition of inhaled vapors, in: D.E. Gardner, J.D. Crapo, R.O. McClellan (Eds.), Toxicology of the Lung, 2nd edn, Raven Press, New York, 1993, pp. 461-483.
38. J.J. Gumucio, D.L. Miller, Functional implications of liver cell heterogeneity, Gastroenterology 80 (1981) 393-403.
39. B.A. Saville, M.R. Gray, Y.K. Tam, Models of hepatic drug elimination, Drug Metab. Rev. 24 (1992) 49-88.
40. D.M. Wilson, T.L. Goldsworthy, J.A. Popp, B.E. Butterworth, Evaluation of genotoxicity, pathological lesions and cell proliferation in livers of rats and mice treated with furan, Environ. Mol. Mutagen. 19 (1992) 209-222.
41. National Toxicology Program, Toxicology and carcinogenesis studies of furan in F-344/N rats and B6C3F1 mice, NTP Technical Report #402, U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC, 1993.
42. 14C]-furan in the male F-344 rat, J. Toxicol. Environ. Health 34 (1991) 245-257.
43. L.-J. Chen, S.S. Hecht, L.A. Peterson, Identification of cis-2-butene-1,4-dial as a microsomal metabolise of furan, Chem. Res. Toxicol. 8 (1995) 903-906.
44. Y. Masuda, N. Nakayama, A. Yamaguchi, M. Murohashi, The effects of diethyidithiocarbamate and carbon disulfide on acute nephrotoxicity induced by furan, bromobenzene and cephaloridine in mice, Jpn. J. Pharmacol. 34 (1984) 221-229.
45. M.A. Carfagna, S.D. Held, G.L. Kedderis, Furan-induced cytolethality in isolated rat hepatocytes: Correspondence with in vivo dosimetry, Toxicol. Appl. Pharmacol. 123 (1993) 265-273.
46. N. Perrot, B. Nalpas, C.S. Yang, P.H. Beaune, Modulation of cytochrome P450 isozymes in human liver by ethanol and drug intake, Eur. J. Clin. Invest. 19 (1989) 549-555.
47. J. Mordenti, Man versus beast: Pharmacokinetic scaling in mammals, J. Pharm. Sci. 75 (1986) 1028-1040.
48. R.L. Dedrick, D.D. Forrester, Blood flow limitations in interpreting Michaelis constants for ethanol oxidation in vivo, Biochem. Pharmacol. 22 (1973) 1133-1140.
49. D.G. Shand, R.E. Rangno, The disposition of propranolol. I. Elimination during oral absorption in man, Pharmacology 7 (1972) 159-168.
50. R.L. Wolen, C.M. Gruber, G.F. Kiplinger, N.E. Scholz, Concentration of propoxyphene in human plasma following oral, intramuscular and intravenous administration, Toxicol. Appl. Pharmacol. 19 (1971) 480-492.
51. R.N. Boyes, D.B. Scott, P.J. Jebson, M.J. Godman, D.G. Julian, Pharmacokinetics of lidocaine in man, Clin. Pharmacol. Ther. 12 (1971) 105-116.
52. B. Åblad, K.O. Borg, G. Johnson, C.G. Regårdh, L. Sölvell, Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxyalprenolol in man, Life Sci. 14 (1974) 693-704.
53. B.K. Park, N.R. Kitteringham, M. Pirmohamed, G.T. Tucker, Relevance of induction of human drug-metabolizing enzymes: Pharmacological and toxicological implications, Brit. J. Clin. Pharmacol. 41 (1996) 477-491.
54. G.R. Wilkinson, Pharmacokinetics of drug disposition: Hemodynamic considerations, Annu. Rev. Pharmacol. 15 (1975) 11-27.
55. G.R. Wilkinson, D.G. Shand, A physiological approach to drug clearance, Clin. Pharmacol. Ther. 18 (1975) 377-390.
56. G.L. Kedderis, Hepatic blood flow limitation of the bioactivation of hazardous chemical air pollutants, Fund. Appl. Toxicol. 30 (1996) 34-35.